Jorge Joven, MD, PhD

Professor of Medicine, Unitat de Recerca Biomèdica (Biomedical Research Unit), Universitat Rovira i Virgili, Hospital Sant Joan de Reus, Institut d’Investigació Sanitària Pere Virgili, Reus (Tarragona), Spain

Dr. Jorge Joven is currently Professor of Medicine and Director of the Unitat de Recerca Biomèdica at the Universitat Rovira I Virgili. He became MD at the University of Barcelona and followed the path towards obtaining the degree in Clinical Biochemistry at the Hospital Vall d’Hebrón from where his tasks in medical care have been developed at the Hospital Sant Joan in Reus for the last 30 years as Head of department in clinical laboratories with responsibilities in biochemistry, hematology, microbiology and pathology. He has also served as President of the Ethical Committee of Clinical Research for 14 years in the same Institution. The teaching and research trajectory has elapsed from the University of Barcelona and Universitat Autònoma de Barcelona to the Universitat Rovira i Virgili. His PhD dissertation on lipoprotein metabolism and atherosclerosis was awarded in 1984, followed by relevant and satisfactory ​​post-doctoral stays at the University of Washington in Seattle and the Tufts University in Boston. These were the old days in which there were no available treatment to treat lipoprotein disorders. Once available these tools we moved to a time in which there were no suitable treatment for atherosclerosis and other non-communicable diseases, or at least, much deeper knowledge is required to manage these diseases. In this context, the trajectory has been long and successful, mainly due to the quality of the human and material resources arranged and leadership to meet planned goals. As a result of combined work, the Unit has trained many PhD students with successful careers in clinical research and have been published more than 400 articles, as well as books, book chapters, clinical guides, and other teaching material. The key to lead clinical and research teams is relatively simple when considering and taking advantage of the ideas and abilities of each member, managing emotions and maintaining goals oriented to motivate continuous improvement. The Unit has demonstrated ability to manage more than 80 projects including clinical trials, commitments to related Industries and academic competitive projects. The Unit has been steadily extending a complex collaboration network throughout Spain, Europe and the United States. The last 10 years have been oriented towards understanding obesity and its metabolic complications, especially diabetes, non-alcoholic fatty liver disease, cancer and arteriosclerosis, the leading causes of morbidity and mortality worldwide. It is now clear that deciphering key mechanisms coordinating nutrition, metabolism, epigenetics, oxidation and inflammation may lead to combined and effective treatments. Current challenges include the understanding of the metabolo-epigenetics clues governing metabolic flexibility and disease-induced metabolic reprogramming. In pursuing these goals, we have learned, not without fuss, that working alone allows reaching limited goals more quickly and without excessive effort, but that we go much further by forming multidisciplinary teams. The reader may find more information at https://www.ncbi.nlm.nih.gov/pubmed/?term=joven+j+OR+joven+maried